From: "ROOT" <root@sctimst.ac.in> **To:** "ROOT" <root@sctimst.ac.in>

Date: 25/11/2024 03:41 PM **Subject:** Invitation for CGR

From: "RRC Rishikesh (rrcrishikesh@aiimsrishikesh.edu.in)" <rrcrishikesh@aiimsrishikesh.edu.in>

To: Meenu Singh <meenusingh4@gmail.com> Date: Mon, 25 Nov 2024 14:58:31 +0530 Subject: [EXTERNAL MAIL] Invitation for CGR

Greetings from AIIMS, Rishikesh!!

The CGR will be held on the Nov 26, 2024 in CPD Hall, AIIMS Rishikesh from 8:00 AM to 9:00 AM. You can join online through the following link:

Meeting link:

https://aiimsrishikesh.webex.com/aiimsrishikesh/j.php?MTID=md58c3c69a0db89f8189469961dc5e90c

Tuesday, Nov 26, 2024, 8:00 AM | (UTC+05:30) Chennai, Kolkata, Mumbai, New Delhi

Meeting number: 2517 804 8289

Meeting password: 261124

Thanks & Regards
Regional Resource Centre
Dept of Telemedicine
AIIMS Rishikesh

DEPARTMENT OF PHYSIOLOGY

(JOURNAL CLUB- 26TH NOVEMBER 2024)

Name of article	Home Blood Pressure Self-monitoring plus Self-titration of Antihypertensive Medication for Poorly Controlled Hypertension in Primary Care: the ADAMPA Randomized Clinical Trial
Journal	Journal of General Internal Medicine
Impact Factor	6.473
Presentor	Dr. Ashutosh Kashyap
Moderator	Dr. Poorvi Kulshreshtha

Abstract

BACKGROUND: Patient empowerment through pharmacological self-management is a common strategy in some chronic diseases such as diabetes, but it is rarely used for controlling blood pressure.

OBJECTIVE: This study aimed to assess self-monitoring plus self-titration of antihypertensive medication versus usual care for reducing systolic blood pressure (SBP) at 12

months in poorly controlled hypertensive patients.

DESIGN: The ADAMPA study was a pragmatic, controlled, randomized, non-masked clinical trial with two parallel arms in Valencia, Spain.

PARTICIPANTS: Hypertensive patients older than 40 years, with SBP over 145 mmHg and/or diastolic blood pressure (DBP) over 90 mmHg, were recruited from July 2017 to June 2018.

INTERVENTION: Participants were randomized 1:1 to usual care versus an individualized, pre-arranged plan based on self-monitoring plus self-titration.

MAIN MEASURE: The primary outcome was the adjusted mean difference (AMD) in SBP between groups at 12 months.

KEY RESULTS: Primary outcome data were available for 312 patients (intervention n=156, control n=156) of the 366 who were initially recruited. The AMD in SBP at 12 months (main analysis) was–2.9 mmHg (95% CI, –5.9 to 0.1, p=0.061), while the AMD in DBP was–1.9 mmHg (95% CI, –3.7 to 0.0, p=0.052). The results of the subgroup analysis were consistent with these for the main outcome measures. More patients in the intervention group achieved good blood pressure control (<140/90 mmHg) at 12 months than in the control group (55.8% vs 42.3%, difference 13.5%, 95% CI, 2.5 to 24.5%, p=0.017). At 12 months, no differences were observed in behavior, quality of life, use of health services, or adverse events.

CONCLUSION: Self-monitoring plus self-titration of anti-hypertensive medication based on an individualized pre-arranged plan used in primary care may be a promising strategy for reducing blood pressure at 12 months compared to usual care, without increasing healthcare utilization or adverse events.

TRIAL REGISTRATION: EudraCT, number 2016-003986-25 (registered 17 March 2017) and clinicaltrials.gov, NCT03242785.

Attachments:

File: 11606 2022 Article 7791.pdf Size: 988k Content Type: application/pdf